Sanofi (NASDAQ:SNY) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a research note published on Wednesday morning.

A number of other equities analysts also recently issued reports on the company. Argus increased their price target on Sanofi from $55.00 to $60.00 and gave the stock a buy rating in a research report on Friday, July 26th. Citigroup raised Sanofi to a strong-buy rating in a research note on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $57.50.

Sanofi Stock Performance

SNY opened at $55.47 on Wednesday. The firm has a fifty day moving average price of $55.52 and a 200 day moving average price of $51.09. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97. The stock has a market cap of $140.76 billion, a P/E ratio of 27.87, a P/E/G ratio of 1.58 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. During the same quarter in the prior year, the firm posted $0.95 earnings per share. The company’s revenue was up 7.8% compared to the same quarter last year. Equities research analysts anticipate that Sanofi will post 4.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Scotia Capital Inc. boosted its position in Sanofi by 186.8% during the fourth quarter. Scotia Capital Inc. now owns 13,411 shares of the company’s stock worth $667,000 after acquiring an additional 8,735 shares during the last quarter. Jones Financial Companies Lllp grew its position in shares of Sanofi by 197.5% in the fourth quarter. Jones Financial Companies Lllp now owns 1,050 shares of the company’s stock valued at $52,000 after purchasing an additional 697 shares in the last quarter. Peapack Gladstone Financial Corp increased its holdings in shares of Sanofi by 63.0% in the fourth quarter. Peapack Gladstone Financial Corp now owns 27,524 shares of the company’s stock valued at $1,369,000 after purchasing an additional 10,641 shares during the last quarter. First Trust Advisors LP boosted its stake in Sanofi by 10.3% during the fourth quarter. First Trust Advisors LP now owns 1,355,033 shares of the company’s stock worth $67,386,000 after buying an additional 127,006 shares during the last quarter. Finally, Lake Street Advisors Group LLC purchased a new stake in Sanofi in the 4th quarter valued at $286,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.